This discrepancy underscores the limitations of targeting “SOD1”, which accounts for only 2% of ALS cases, with mutation-specific responses (A4V vs D90A) further complicating therapeutic efficacy. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.